AUTHORS
Nishi Shah, MD, MPH, Richa Parikh, MD2, Nisha Joseph, MD3, Craig Hofmeister, MD, MPH4, Sara Scott5, Danielle Roberts, MD6, Vikas Gupta, MD, PhD7, Jonathan L Kaufman, MD8, Roberto Mina9, Ajay K Nooka, MD, MPH10, Sagar Lonial, MD, FACP11
AFFILIATIONS
1 Winship Cancer Institute, Atlanta, Georgia
2 Winship Cancer Institute, Atlanta, Georgia
3 Winship Cancer Institute, Atlanta, Georgia
4 Winship Cancer Institute, Atlanta, Georgia
5 Winship Cancer Institute, Atlanta, Georgia
6 Winship Cancer Institute, Atlanta, Georgia
7 Winship Cancer Institute, Atlanta, Georgia
8 Winship Cancer Institute, Atlanta, Georgia
9 Winship Cancer Institute, Atlanta, Georgia
10 Winship Cancer Institute, Atlanta, Georgia
11 Winship Cancer Institute, Atlanta, Georgia
ABSTRACT
Carvykti, a BCMA directed CAR-T cell therapy is increasingly being used for relapsed/refractory MM. Unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival. However, there are emerging reports that suggest use of IMIDs or Celmods could potentially improve T-cell fitness.
The aim of this retrospective analysis is to evaluate the safety and toxicity of pomalidomide as maintenance in multiple myeloma patients who have received carvykti as standard of care at Winship Cancer institute. The patients were started on pomalidomide at the discretion of treating oncologist. For patients with ongoing cytopenia, pomalidomide was deferred. Pomalidomide was started at month 3 and continued until 1 year post CAR-T.
Between 8/2022 to 5/4/2026, 238 patients received Carvykti commercially. Of the total 238 patients who received carvykti, 107 (45%) were females. 52.9% were whites, 42.8% were African American. Median age at the time of Carvykti infusion was 65 years (Range 38-85 years) Pomalidomide was initiated as maintenance therapy in 45 patients. 5 could not tolerate it due to cytopenia, pneumonitis or drug rash. 40 patients (16.8%) have been started on pomalidomide from day 90 with the intent to continue until 1 year post CAR-T. Median follow-up for the entire cohort is 375 days( 19-1253 days)
Median PFS is 1060 days ( 95% CI 875-1110 days). Median PFS is not statistically different for patients based on use of pomalidomide maintenance. Out of 238 patients, immune mediated events were observed in 32 patients (13.4%). Amongst patients on pomalidomide maintenance, immune mediated events were seen in 3 patients (7.5%). Secondary malignancies were seen in 13 patients (5.4%). In patients on pomalidomide maintenance, secondary cancers were seen in 4 patients (10%).
Long term follow-up will be crucial to understand the impact of pomalidomide on PFS. Updated results will be presented at ASH. Based on the current results, pomalidomide as maintenance therapy appears safe. Long term follow-up of these patients will provide valuable information on the effectiveness of this drug as maintenance therapy.
DISCLOSURES
Nishi Shah, MD, MPH: Clinical trial -IGI, MMRC - Research Funding